Effect of Early Heparin Anticoagulation on Blood Flow and Cardiac Function in Patients with Acute ST Segment Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention
DOI:
https://doi.org/10.59958/hsf.7269Keywords:
acute ST-segment elevation myocardial infarction, primary percutaneous coronary intervention, unfractionated heparin, myocardial perfusion, cardiac functionAbstract
Objective: This study aimed to investigate the effect of early administration of heparin anticoagulation on blood flow and cardiac function in patients with acute ST segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PPCI). Methods: A retrospective analysis was conducted on 730 patients with STEMI who underwent PPCI at the Department of Cardiology of the Chengdu Fifth People's Hospital of Chengdu from December 2017 to May 2023. According to the timing of heparin administration. The patients were divided into two groups based on the timing of heparin administration: the early group (3000 U unfractionated heparin administered immediately after the diagnosis of STEMI) and the delayed group (Intravenous injection of ordinary heparin 3000 U after successful interventional catheterization following the diagnosis of STEMI). The study compared general clinical data, myocardial injury markers (initial troponin, peak troponin, and tmax troponin), interventional related indicators (preprocedural thrombolysis in myocardial infarction (TIMI) flow grade, postprocedural TIMI flow grade, stent length, and thrombus aspiration), and postoperative indexes ST segment resolution (STR), left ventricular ejection fraction (LVEF), n-terminal pro-brain natriuretic peptide (NT-proBNP), major adverse cardiovascular events (MACE), and bleeding events. Results: The early group had a lower proportion of TIMI 0–1 grade and a higher proportion of TIMI 2–3 grade compared to the delayed group (p < 0.05). The early group showed better ST segment resolution (p < 0.05). There was no significant difference in LVEF and NT-proBNP classification between the two groups (p > 0.05). Subgroup analysis suggested an interaction between early heparin anticoagulation and left anterior descending infarct-related artery (IRA) on cardiac function. There was no significant difference in the incidence of MACE and bleeding events between the two groups (p > 0.05). Logistic regression analysis revealed that early heparin anticoagulation was a predictor of immediate TIMI grade 2–3 flow, and TIMI grade 2–3 flow was negatively correlated with early heparin anticoagulation. Conclusions: Early heparin anticoagulation can improve the patency of the IRA and myocardial perfusion in patients with STEMI. Additionally, it can reduce myocardial injury and improve cardiac function without increasing the risk of in-hospital bleeding.
References
Li SY, Zhou MG, Ye T, Cheng LC, Zhu F, Cui CY, et al. Frequency of ST-segment elevation myocardial infarction, non-ST-segment myocardial infarction, and unstable angina: results from a Southwest Chinese Registry. Reviews in Cardiovascular Medicine. 2021; 22: 239–245.
Bhatt DL, Lopes RD, Harrington RA. Diagnosis and Treatment of Acute Coronary Syndromes: A Review. JAMA. 2022; 327: 662–675.
Ouaddi NE, de Diego O, Labata C, Rueda F, Martínez MJ, Cámara ML, et al. Mechanical complications in STEMI: prevalence and mortality trends in the primary PCI era. The Ruti-STEMI registry. Revista Espanola De Cardiologia (English Ed.). 2023; 76: 427–433.
Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. European Heart Journal. 2023; 44: 3720–3826.
Surve TA, Kazim MA, Sughra M, Mirza AMW, Murugan SK, Shebani KAM, et al. Revascularization Modalities in Acute Coronary Syndrome: A Review of the Current State of Evidence. Cureus. 2023; 15: e47207.
Chacón-Diaz M, Custodio-Sánchez P, Rojas De la Cuba P, Yábar-Galindo G, Rodríguez-Olivares R, Miranda-Noé D, et al. Outcomes in ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention or pharmacoinvasive strategy in a Latin American country. BMC Cardiovascular Disorders. 2022; 22: 296.
Dauerman HL, Ibanez B. The Edge of Time in Acute Myocardial Infarction. Journal of the American College of Cardiology. 2021; 77: 1871–1874.
Kastrati A, Coughlan JJ, Ndrepepa G. Primary PCI, Late Presenting STEMI, and the Limits of Time. Journal of the American College of Cardiology. 2021; 78: 1306–1308.
Tang N, Chen X, Li K, Li H, Qi C. Myocardial Perfusion in ST-Segment Elevation Myocardial Infarction Patients After Percutaneous Coronary Intervention: Influencing Factors and Intervention Strategies. Cureus. 2023; 15: e42841.
Poston RN, Chughtai J, Ujkaj D, Louis H, Leake DS, Cooper D. Monocytic Cell Adhesion to Oxidised Ligands: Relevance to Cardiovascular Disease. Biomedicines. 2022; 10: 3083.
Ranjbar A, Sohrabi B, Sadat-Ebrahimi SR, Ghaffari S, Kazemi B, Aslanabadi N, et al. The association between T wave inversion in leads with ST-elevation and patency of the infarct-related artery. BMC Cardiovascular Disorders. 2021; 21: 27.
Dong Q, Wen X, Chang G, Xia R, Wang S, Yang Y, et al. ST-segment resolution as a marker for severe myocardial fibrosis in ST-segment elevation myocardial infarction. BMC Cardiovascular Disorders. 2021; 21: 455.
Wang Z, Peng J. The predictive value of the nomogram model of clinical risk factors for ischemia-reperfusion injury after primary percutaneous coronary intervention. Scientific Reports. 2023; 13: 5084.
Giralt T, Ribas N, Freixa X, Sabaté M, Caldentey G, Tizón-Marcos H, et al. Impact of pre-angioplasty antithrombotic therapy administration on coronary reperfusion in ST-segment elevation myocardial infarction: Does time matter? International Journal of Cardiology. 2021; 325: 9–15.
Giralt T, Carrillo X, Rodriguez-Leor O, Fernandez-Nofrerias E, Rueda F, Serra-Flores J, et al. Time-dependent effects of unfractionated heparin in patients with ST-elevation myocardial infarction transferred for primary angioplasty. International Journal of Cardiology. 2015; 198: 70–74.
Maioli M, Zeymer U, van 't Hof AWJ, Gibson CM, Dudek D, Bellandi F, et al. Impact of preprocedural TIMI flow on myocardial perfusion, distal embolization and mortality in patients with ST-segment elevation myocardial infarction treated by primary angioplasty and glycoprotein IIb/IIIa inhibitors. The Journal of Invasive Cardiology. 2012; 24: 324–327.
Collet JP, Zeitouni M. Heparin pretreatment in STEMI: is earlier always better? EuroIntervention: Journal of EuroPCR in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 2022; 18: 697–699.
Maruszak N, Pilch W, Januszek R, Malinowski KP, Surdacki A, Chyrchel M. Risk Factors of Suboptimal Coronary Blood Flow after a Percutaneous Coronary Intervention in Patients with Acute Anterior Wall Myocardial Infarction. Journal of Personalized Medicine. 2023; 13: 1217.
Fakhr-Mousavi A, Cheshmkhorooshan S, Vakilpour A, Mousavi SM. The effect of heparin administration time on thrombolysis in myocardial infarction flow grade in patients with acute ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. ARYA Atherosclerosis. 2022; 18: 1–7.
Galli M, Niccoli G, De Maria G, Brugaletta S, Montone RA, Vergallo R, et al. Coronary microvascular obstruction and dysfunction in patients with acute myocardial infarction. Nature Reviews. Cardiology. 2023. (online ahead of print)
Wu C, Gao X, Li L, Jing Q, Li W, Xu H, et al. Role of ST-Segment Resolution Alone and in Combination With TIMI Flow After Primary Percutaneous Coronary Intervention for ST-Segment-Elevation Myocardial Infarction. Journal of the American Heart Association. 2023; 12: e029670.
Kleinbongard P, Heusch G. A fresh look at coronary microembolization. Nature Reviews. Cardiology. 2022; 19: 265–280.
Fabris E, Ten Berg JM, Hermanides RS, Ottervanger JP, Dambrink JHE, Gosselink AM, et al. NT-proBNP level before primary PCI and risk of poor myocardial reperfusion: Insight from the On-TIME II trial. American Heart Journal. 2021; 233: 78–85.
Wang JL, Guo CY, Li HW, Zhao XQ, Zhao SM. Prognostic Value of NT-proBNP in Patients With Successful PCI for ACS and Normal Left Ventricular Ejection Fraction. The American Journal of the Medical Sciences. 2022; 363: 333–341.
Albuquerque F, Gomes DA, Ferreira J, de Araújo Gonçalves P, Lopes PM, Presume J, et al. Upstream anticoagulation in patients with ST-segment elevation myocardial infarction: a systematic review and meta-analysis. Clinical Research in Cardiology. 2023; 112: 1322–1330.
Emilsson OL, Bergman S, Mohammad MA, Olivecrona GK, Götberg M, Erlinge D, et al. Pretreatment with heparin in patients with ST-segment elevation myocardial infarction: a report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). EuroIntervention: Journal of EuroPCR in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 2022; 18: 709–718.
Albuquerque F, Gomes DA, Ferreira J, de Araújo Gonçalves P, Lopes PM, Presume J, et al. Upstream anticoagulation in patients with ST-segment elevation myocardial infarction: a systematic review and meta-analysis. Clinical Research in Cardiology: Official Journal of the German Cardiac Society. 2023; 112: 1322–1330.
Kheifets M, Vaknin-Assa H, Greenberg G, Orvin K, Assali A, Kornowski R, et al. Trends in ST-elevation myocardial infarction. Coronary Artery Disease. 2022; 31: 1–8.
Urban P, Gregson J, Owen R, Mehran R, Windecker S, Valgimigli M, et al. Assessing the Risks of Bleeding vs Thrombotic Events in Patients at High Bleeding Risk After Coronary Stent Implantation: The ARC-High Bleeding Risk Trade-off Model. JAMA Cardiology. 2021; 6: 410–419.
